Biopharmaceutical Services

 For many years, India has produced over half the world’s vaccine supply (World Health Organization), as well as a large chunk of its generic pharmaceuticals and biosimilars,cementing its reputation as “the pharmacy of the world.” Today, these Indian companies are innovating new drugs, buying assets in the West and moving up the value chain.

For forward-thinking global biopharmaceutical companies, India’s life sciences ecosystem, a dense network of advanced manufacturers, CROs (Contract Research Organizations), and elite research institutions, offers a competitive edge for global R&D.

Biotechnology startups and enterprise pharma firms across the United States and Europe face a common challenge: the need to accelerate clinical timelines and lower their R&D burn rates while maintaining absolute data integrity. By expanding into the Indian ecosystem, companies tap into a pool of over two million annual STEM graduates and gain access to more U.S. FDA-approved manufacturing facilities than any other country outside the United States  (Sources: Center for Security and Emerging Technology, U.S. Food and Drug Administration).

How Amritt Helps Biopharma Companies in India

Amritt advises international biopharmaceutical companies, evaluating how India fits into their global research, development, and manufacturing strategies. With over two decades of experience, we specialize in providing high-quality, customized intelligence and facilitating entry into India, ensuring you connect with the most trusted partners for your most critical studies.

India’s commitment to the life sciences is evident in its robust talent base of educated researchers, chemists, and scientists who possess extensive expertise in modern biopharmaceutical studies. This talent, combined with robust infrastructure and government support for technology parks, creates an environment where complex R&D can flourish at a significantly lower operational cost and quicker turnaround times than in the West. By leveraging these strengths, your company can achieve critical milestones while retaining budget flexibility.

Amritt’s Biopharmaceutical Services

Since 2003, Amritt has advised international biotechnology, pharmaceutical, and medical device companies seeking to engage in India’s life sciences ecosystem. Some of our services include:

• PreClinical Services
  • Sourcing and managing partners for essential studies, including toxicology and PK/PD, for efficient and cost-effective product development.
• Clinical Trials
  • Oversight of complex Phase IB–IV clinical trials through vetted Contract Research Organizations, ensuring quality and global regulatory compliance.
• Sourcing of APIs and excipients
  • India stands among the world’s most significant producers of Active Pharmaceutical Ingredients, the biologically active components that give medicines their therapeutic effect. As of 2026, India hosts about 500 active pharmaceutical ingredient producers, many of whose products are approved by the US FDA and other global regulatory agencies.

• Flow Chemistry and Biocatalysis
  • Connecting clients to specialized research institutes with expertise in cutting-edge methods such as Flow Chemistry, Biocatalysis, and complex molecule creation.
• Creating Biosimilars
  • Identifying opportunities and partners for the creation, development, and high-quality manufacturing of biosimilars and generics, leveraging India’s core strengths.

If your program requires capabilities beyond those described above, Amritt can identify and qualify specialized partners across India’s life sciences ecosystem.

Top Decisions That Shape Successful Biopharmaceutical Programs in India

The success of a biopharmaceutical program in India is often determined long before the first study begins. Experienced teams focus on five key decisions:

• Determining whether India is the right fit for your objectives
• Selecting which activities belong in India
• Choosing partners that match your scientific and regulatory requirements
• Establishing effective governance and communication
• Defining success before the program begins

Amritt helps clients answer these questions, evaluate their options, and identify partners that best align with their scientific, regulatory, and commercial objectives.